UNSPSC 51402102: Dichlormezanone

This classification denotes a sedative and hypnotic with the molecular formula C11H11Cl2NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TO4OC41XVI, chemically known as 4-metathiazanone, 2-(3,4-dichlorophenyl)-3-methyl-, 1,1-dioxide but generally known as dichlormezanone, which bears US NIH Compound Identifier 71209. European Medicines Agency schedules Dichlormezanone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07084MIG.

UNSPSC 51402102 Dichlormezanone is a Commodity code, but the recent state and local opportunities posted under it do not reflect purchases of dichlormezanone itself — a sedative pharmaceutical ingredient. Instead, the code sees activity tagged to broader pharmaceutical and medical-supply procurement, including naloxone distribution, therapeutic pharmacy initiatives, and multi-source generic pharmaceuticals and over-the-counter products for health and human services agencies. The mismatch suggests either systematic miscoding in source systems or that this code has drifted from its nominal scope in state and local classification practice. State and local issuers include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP).

Recent activity spans Florida, Texas, and the MMCAP multi-state cooperative footprint (including Minnesota and Oregon). Three representative opportunities illustrate the breadth: Seminole County's competitive IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 annual units of naloxone and 800 safe drug deactivation systems with quarterly delivery to its community health building; Texas HHS Commission issued a Request for Information (RFI HHS0017013, due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels; and MMCAP released a multi-award RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through designated wholesalers, with award expected July 1, 2026. The MMCAP RFP signals sustained cooperative purchasing activity for pharmaceutical supply chains serving state and local facilities across multiple jurisdictions.